Prulacabtagene leucel

普勒基仑赛

Report date: 2026/04/17 20:02:02

Base Information

Drug NamePrulacabtagene leucel
Drug Alias NameADI-001 CD20 gamma delta CAR-TADI-001 (Allogeneic gamma delta (γδ) CAR T cell therapy)ADI-001
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaAutoimmune DiseasesScleroderma, Systemic +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAdicet Bio IncRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Adicet Biotechnology Co LtdCharles River Laboratories IncAdicet Bio Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesScleroderma, SystemicLupus Erythematosus, Systemic +[14] 
Inactive IndicationsPrimary mediastinal B cell lymphoma

Other Information

ATC CodeN/A
Related LinksN/A